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Background: Drug costs increasingly pose a burden upon the otherwise inadequate health care resources and
rational drug utilization is an important segment of every national health policy. Optimal patient care should be the
goal of rational pharmacotherapy, whereby the economic burden of treatment is just one of the elements to be
considered on choosing appropriate therapy.
The aim of this study was to determine distribution and trends in the outpatient utilization of generic versus
brand name psychopharmaceuticals and to evaluate the rationality of prescribing psychopharmaceuticals during
a ten-year period.
Methods: Using the World Health Organization Anatomical-Therapeutic-Chemical classification/Defined Daily Doses
(ATC/DDD) methodology, the number of DDD was calculated from data collected from pharmacies on the number
and size of drug packages. The ratio of generic and brand name drug costs served as an indicator on assessing the
rationality of drug utilization.
Results: Total cost for psychopharmaceuticals increased by 20.1%, more for brand name than for generic
agents (32.7% vs. 7.4%). The highest share of generic psychopharmaceuticals as compared with brand name
drugs according to DDD per 1000 inhabitants per day (DDD/1000/day) was in the group of psycholeptics
(83.6% in 2001 vs. 82.2% in 2010), most in hypnotics and sedatives, and least in antipsychotics. The share of generic
psychopharmaceuticals in total drug utilization according to financial indicators decreased by 9.6% and according
to DDD/1000/day by 12%. The greatest decrease was in antidepressants, i.e. by 33.8% according to financial
indicators and by 46% according to DDD/1000/day; and in antipsychotics by 30.9% according to DDD/1000/day,
while showing an increase by 8.5% according to financial indicators. In the therapeutic subgroup of mood
stabilizers, the share of generic drugs in total drug utilization declined by 32% according to DDD/1000/day, but
increased by 25.1% according to financial indicators.
Conclusions: The lack of uniform national guidelines and the still strong impact of pharmaceutical industry
marketing continue favoring the rise in prescribing brand name antidepressants and antipsychotics. Depression,
schizophrenia and bipolar diseases are complex diseases. As a result, specific measures are needed to encourage
the prescribing of generic psychopharmaceuticals.
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Drug costs increasingly pose a burden upon the other-
wise inadequate health care resources and rational drug
utilization is an important segment of every national
health policy [1]. The rising drug cost is influenced by
the increasing number of new drugs, which as a rule are
more expensive [2,3]. Another factor influencing the ris-
ing drug cost is the prolonged life expectancy, along
with the ever growing share of chronic diseases in the
cost of pharmacotherapy and treatment in general [4].
In addition, neither should the impact of drug manufac-
turers and distributors, the attitudes, knowledge and
personal characteristics of physicians, patient demands
and expectations, healthcare structure, and governmen-
tal regulatory institutions and measures be neglected.
Rational pharmacotherapy implies the right agent pre-
scribed in the right dosage to the right patient for the re-
quired period at the lowest cost for the individual and
the community [2,3,5]. Optimal patient care should be
the goal of rational pharmacotherapy, whereby the eco-
nomic burden of treatment is just one of the elements to
be considered on choosing appropriate therapy [3,5].
Many European Union (EU) countries have successfully
rationalized drug consumption by stimulating prescribing
generic drugs, which are less expensive and as efficacious
as brand name ones [4,6-9].
This is especially the case when physicians are being
encouraged through a variety of measures to preferen-
tially prescribe generics [4].
During the last decade, the tools of external price
referencing (international price comparisons) and refer-
ence price systems (limitation of reimbursement for
identical or similar medicines in a cluster) have been in-
creasingly used in several EU Member States. External
price referencing is a common pricing procedure applied
in 22 EU Member States [8].
In an attempt to bring measures to reduce the excessive
financial costs for drugs and to rationalize drug utilization
in general, during the study period the Croatian healthcare
policy makers have enacted a number of bylaws and acts
primarily aimed at drug consumption rationalization
through direct or indirect means. In 2001, a new Act on
Health Insurance was enacted [2]. In the same year, the
Croatian Institute of Health Insurance (CIHI) issued a
Directive on the List of Drugs, based on the Act, which in-
cluded all the drugs that could be prescribed or adminis-
tered during treatment at healthcare institutions in the
Republic of Croatia. The List also regulated the level of
patient co-payment for particular drugs [2,10]. In 2002,
the Ministry of Health of the Republic of Croatia issued
the Bylaw on the Conditions and Implementation of Sup-
plementary Health Insurance [11]. In 2004, aiming at drug
cost containment, the Bylaw Regulating Wholesales Drug
Pricing Policy and Reporting on Wholesale Prices wasenacted, on the model of other European countries. Ac-
cording to the Bylaw, the criteria for wholesale drug pri-
cing were their comparative prices in other countries, the
level of their wholesale comparative prices, pharmacoe-
conomic studies, and reference price [12]. Comparative
wholesale drug price was based on the same drug (of iden-
tical generic entity and identical pharmaceutical formula-
tion) wholesale price in Italy, France and Slovenia. If data
on the respective drug prices in these countries were lack-
ing, then the prices in Spain and Czech Republic were
taken for comparison. Since 2009, in order to be included
in the essential CIHI list of drugs, the wholesale prices of
the patented drugs should be by at least 10% lower than
the average prices of the brand name drugs in the men-
tioned countries. The drugs that are not patent protected
anymore should be cheaper by at least 35%, whereas the
prices of generic drugs should be by at least 30% lower
than their average prices in Italy, France and Slovenia.
Only brand name drugs that contain a completely new ac-
tive ingredient and appear on the Croatian market for the
first time can have the same price as in the comparison
countries, whereas the price of a drug of the same unpro-
tected name cannot exceed 90% of the price of the last
identical generic added to the list [8,13].
In 2006, CIHI introduced two drug lists: main essential
list containing all essential drugs covered by compulsory
health insurance and supplementary list of drugs in part
covered from compulsory health insurance and in part
by the patients [14-16].
The Bylaw on the Policy of Including Drugs in the
CIHI Essential and Supplementary list of Drugs has im-
proved the methodology of issuing recommendations for
drug placement on the list. Mandatory reporting on all pro-
motion costs and financial transactions between pharma-
ceutical industry and physicians working in public health
establishments has also been introduced [16].
Therefore, the aim of the present study was to deter-
mine distribution and trends in outpatient utilization of
generic versus brand name psychopharmaceuticals in the
City of Zagreb during the 2001–2010 period.
Methods
In this retrospective, descriptive research, data on the num-
ber of drug packages and buying price for all prescription
drugs registered in the Republic of Croatia were collected
from all Zagreb pharmacies during the 2001–2010 period.
In order to make the data standardized and compar-
able with other settings, the World Health Organization
Anatomical-Therapeutic-Chemical classification/Defined
Daily Doses (ATC/DDD) methodology was used on asses-
sing drug utilization [17].
The ratio of generic and brand name psychopharma-
ceutical costs served as an indicator on assessing the ra-
tionality of drug utilization [18]. The ratio of generic to
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by the following formulas:
Pharmaceutical expenditure for generic products €ð Þ
Generic drugs ¼ −−−−−−−−−−−−−−−−−−−−−−−−−−− x 100
Total pharmaceuticl expenditure €ð Þ
Utilisation of generic products in DDDs
Generic drugs ¼ −−−−−−−−−−−−−−−−−−− x 100
Total utilization in DDDs
Pharmaceutical expenditure for new products €ð Þ
Brand name drugs ¼ −−−−−−−−−−−−−−−−−−−−−−−− x 100
Total pharmaceuticl expenditure €ð Þ
Utilisation of new products in DDDs
Brand name drugs ¼ −−−−−−−−−−−−−−−−−−−−−−−−−− x 100
Total utilization in DDDs
Ratio generic drugs/brand name drugs
Descriptive analysis was conducted for quantitative vari-
ables. Excel was used to create the database and to
analyze the data. Data on drug utilization were handled
in compliance with Zagreb Municipal Pharmacy.
Ethics
This study was approved by the Ethics Committee of Dr
Andrija Štampar Institute of Public Health. The research
was in compliance with the Helsinki Declaration.
Results
Outpatient utilization of psychopharmaceuticals (ATC
subgroup N03-N06) in the City of Zagreb in 2001 and
2010, expressed according to financial indicators and
DDD per 1000 inhabitants per day (DDD/1000/day), is
illustrated in Tables 1, 2, 3, 4, 5, 6, 7, 8 and 9.
In 2001, the share of generic psychopharmaceuticals in
total drug utilization was 49.55% and 80.76% according
to financial indicators and DDD/1000/day, respectively
(Tables 1 and 2).
Psycholeptics (ATC subgroup N05) accounted for the
highest share of generic versus brand name psychophar-
maceuticals according to both financial indicators (52%)Table 1 Outpatient utilization of psychopharmaceuticals (ATC
according to financial indicators (€)
ATC code Therapeutic subgroup Generic drugs (€) Brand nam
N03AE-AX Antiepileptics 116 101.72 138 313.4
N04 AA Anticholinergics (biperiden) 0 38 566.1
N05 Psycholeptics 751 795.65 693 849.9
N06A Antidepressants 173 367.48 189 463.97
Total 1 041 264.87 1 060 193.and DDD/1000/day (83.6%). In the N04A therapeutic
subgroup, biperiden was the only agent observed, which
was included in the Croatian Institute of Health Insur-
ance (CIHI) List of Drugs only as brand name drug, thus
precluding consumption of the generic agent.
Outpatient utilization of psycholeptics in the City of
Zagreb in 2001, expressed according to financial indica-
tors and DDD/1000/day is presented in Tables 3 and 4.
The highest consumption of generic drugs was re-
corded in the therapeutic subgroup of hypnotics and
sedatives (96.55% according to financial indicators and
98.82% according to DDD/1000/day) and lowest con-
sumption in the therapeutic subgroup of antipsychotics
(26.41% and 67.57%, respectively).
Outpatient utilization of psychopharmaceuticals (ATC
subgroup N03-N06) in the City of Zagreb in 2010,
expressed according to financial indicators and DDD/
1000/day, is illustrated in Tables 5 and 6.
Outpatient utilization of psycholeptics in the City of
Zagreb in 2010, expressed according to financial indica-
tors and DDD/1000/day is presented in Tables 7 and 8.
The share of generic psychopharmaceuticals in total
drug utilization was 44.78% according to financial indica-
tors and 71.08% according to DDD/1000/day. The highest
consumption was recorded for psycholeptics (ATC sub-
group N05) 46.26% according to financial indicators and
82.02% according to DDD/1000/day) and lowest for biper-
iden (N04A) (0.96% and 1.1%, respectively). These were
followed by the consumption of generic antidepressants,
which accounted for 31.62% according to financial indica-
tors and 39.83% according to DDD/1000/day as compared
with brand name agents.
In 2010, the highest consumption of generic drugs in
the N05 subgroup was recorded in the therapeutic sub-
group of hypnotics and sedatives (94.44% according to fi-
nancial indicators and 97.81% according to DDD/1000/
day) and lowest consumption in the therapeutic subgroup
of antipsychotics (28.65% and 46.67%, respectively).
During the period of observation, the share of generic
psychopharmaceuticals in total drug utilization decreased
by 9.6% according to financial indicators and by 12%
according to DDD/1000/day. The greatest decline was
recorded in the therapeutic subgroup of antidepressants,subgroup N03-N06) in the City of Zagreb in 2001
e drugs (€) Total (€) Share of generics%, Share of brand
name drugs%
254 415.12 45.63 54.37
38 566.10 0 100.00
1 445 645.55 52.00 48.00
362 831.45 47.78 52.22
38 2 101 458.25 49.55 50.45
Table 2 Outpatient utilization of psychopharmaceuticals (ATC subgroup N03-N06) in the City of Zagreb in 2001
according to DDD/1000/day




Total DDD/1000/day Share of generics%
DDD/1000/day
Share of brand name
drugs% DDD/1000/day
N03AE-AX Antiepileptics 3.82 1.24 5.06 75.49 24.51
N04 AA Anticholinergics (biperiden) 0 2.05 2.05 0 100.00
N05 Psycholeptics 78.44 15.38 93.82 83.60 16.40
N06A Antidepressants 7.98 2.83 10.81 73.82 26.18
Total 90.24 21.5 111.74 80.76 19.24
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46% according to DDD/1000/day. In the therapeutic
subgroup of antiepileptics (N03AE-AX), the share of
generic drugs in total drug utilization decreased by 32%
according to DDD/1000/day, but increased by 25.1%
according to financial indicators.
The ratio of generic and brand name psychopharmaceu-
ticals (ATC subgroup N03-N06) in the City of Zagreb in
2001 and 2010 is shown in Table 9. The highest generic/
brand name drug ratio according to DDD/1000/day was
recorded for the group of psycholeptics and lowest for
biperiden and the group of antidepressants. In comparison
with 2001, the ratio showed reduction for all groups indi-
vidually and for all psychopharmaceuticals taken together.
Discussion
One of the ways to rationalize drug utilization and up-
grade the quality of drug prescribing is promotion of
prescribing generic drugs. According to the WHO
(EURO-MED-STAT Group), drug utilization can be con-
sidered rational if the ratio of generic and brand name
drug costs is around 80% in favor of generic drugs [18].
Results of the present study revealed the cost of psycho-
pharmaceuticals in the City of Zagreb to have increased
by 20.1% during the study period, with a significantly
greater increase recorded for brand name drugs as com-
pared with generic drugs (32.7% vs. 7.4%).
Differences were found in the distribution and trends in
the outpatient utilization of generic psychopharmaceuticals
according to both DDD/1000/day and financial indicators.
The rate of prescribing generic psychopharmaceuticals was
lower in 2010 than in 2001 according to both parameters.
In 2001, the share of generic psychopharmaceuticals inTable 3 Outpatient utilization of psycholeptics (ATC subgroup
indicators (€)
ATC code Therapeutic subgroup Generic drugs (€) Bran
drug
N05A Antipsychotics 222 656.01 620 3
N05B Anxiolytics 484 325.92 71 90
N05C Hypnotics and sedatives 44 813.71 1601
N05 Psycholeptics 751 795.65 693 8total drug utilization according to DDD/1000/day was
80.76%, which corresponded with the criterion of rational
consumption. During the study period, however, the share
of generic psychopharmaceuticals in total drug utilization
according to DDD/1000/day declined by 12%, accounting
for 71.08% in 2010, although the number of generic drugs
included in the CIHI List of Drugs had increased. From
2001 to 2010, many changes were made in the CIHI List of
Drugs, which also influenced drug utilization.
Total cost of antidepressants increased from 2001 to
2010 by 32.6%, whereby the cost of generic drugs de-
clined by 12.3%, while the cost of brand name drugs in-
creased b 73.6%. The greatest decline in the share of
generic drugs in total utilization was recorded in this
therapeutic subgroup, i.e. by 33.8% and 46% according
to financial indicators and DDD/1000/day, respectively.
In the therapeutic subgroup of antidepressants included
in the CIHI List of Drugs, the choice to prescribe a gen-
eric or an brand name drug was only possible for fluox-
etine [10], whereas other agents were either generic
(amitriptyline, clomipramine and maprotiline) or brand
name (paroxetine, sertraline, fluvoxamine, tianeptine and
reboxetine). According to DDD/1000/day, consumption
of the generic agent fluoxetine significantly exceeded
consumption of the brand name drug (4.06:0.22).
During the study period, new antidepressants were in-
cluded in the List, as follows: moclobemide (1 brand
name), citalopram (2 generics), escitalopram (1 brand
name and 2 generics), venlafaxine (4 generics), mirtaza-
pine (2 generics) and duloxetine (1 brand name). At the
same time, the number of generic antidepressants previ-
ously included in the List increased, as follows: fluoxet-
ine (1 generic), paroxetine (3 generics) and sertraline (5N05) in the City of Zagreb in 2001 according to financial
d name
s (€)




38.18 842 994.19 26.41 73.59
9.74 556 235.66 87.07 12.93
.97 46 415.68 96.55 3.45
49.9 1 445 645.55 52.00 48.00
Table 4 Outpatient utilization of psycholeptics (ATC subgroup N05) in the City of Zagreb in 2001 according to
DDD/1000/day




Total DDD/1000/day Share of generics%,
DDD/1000/day
Share of brand name
drugs% DDD/1000/day
N05A Antipsychotics 10.49 5.04 15.53 67.54 32.45
N05B Anxiolytics 59.5 10.25 69.75 85.31 14.69
N05C Hypnotics and sedatives 8.45 0.1 8.55 98.82 1.18
N05 Psycholeptics 78.44 15.38 93.82 83.6 16.4
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transferred to the Supplementary list of Drugs with pa-
tient co-payment.
In 2010, the CIHI List of Drugs offered choice on pre-
scribing generic or brand name antidepressant for fluoxet-
ine, escitalopram (supplementary list), paroxetine and
sertraline [19,20]. Although the share of generic fluoxetine
according to DDD/1000/day exceeded the share of brand
name drug (1.18:0.58), it was significantly lower according
to financial indicators. There was no utilization of generic
escitalopram, while consumption of the brand name drug
was 2.34 DDD/1000/day. According to this indicator, the
utilization of generic paroxetine and generic sertraline was
significantly lower in comparison with the brand name
drugs (0.46:3.3 and 0.87:3.58, respectively).
Although a generic drug is therapeutic equivalent to
the brand name one and is of the same quality, safety
and efficacy as the brand name drug, the higher rate of
prescribing brand name, more expensive drugs relies on
the studies suggesting that even minimal variation in
drug bioequivalence and efficacy may play a major role
due to the complex nature of the disease [21,22]. The
more so, a study comparing the economic effect of sub-
stituting brand name selective serotonin reuptake inhibi-
tors (SSRIs) with generic SSRIs in patients with major
depressive disorder pointed to the possible increase in
the overall cost of treatment due to the increased rate of
hospitalization, emergency visits to physician offices and
other associated costs caused by therapy noncompliance
[23]. In contrast, other studies found no statistically sig-
nificant difference in therapy compliance between patients
treated with generic and brand name SSRI/serotonin-Table 5 Outpatient utilization of psychopharmaceuticals (ATC
according to financial indicators (€)
ATC code Therapeutic subgroup Generic drugs (€) Bra
dru
N03AE-AX Antiepileptics 205 294.17 154
N04 AA Anticholinergics (biperiden) 112.79 11
N05 Psycholeptics 760 537.41 911
N06A Antidepressants 152 064.2 328
Total 1 118 008.58 1 4norepinephrine reuptake inhibitor (SNRI) antidepressants,
or between those on generic and brand name escitalopram
[24,25]. Some authors suggest restrictions in prescribing
brand name and newer antidepressants in order to in-
crease the use of generic antidepressants, as a stimulating
measure to modify prescribing habits [4]. Prescribing re-
strictions have been successfully introduced in Austria to
limit the prescribing of atorvastatin and rosuvastatin
versus generic statins. Specific measures in the case of
antidepressants could include academic detailing, pre-
scribing guidance, and prescribing restrictions to encour-
age the prescribing of multiple-sourced antidepressants
such as venlafaxine and mirtazapine where appropriate.
The restricions would limit the prescribing duloxetine to
second line after mirtazapine, or venlafaxine if there are
concerns with their side effects or effectiveness in practice
[4]. In Sweden, prescribing duloxetine is restricted, with
due consideration of individual side effects and efficacy in
practice [4]. The utilization of venlafaxine significantly in-
creased after prescription restrictions for duloxetine [26].
In the chemical-therapeutic subgroup of mood stabi-
lizers (N03AE-AX), total cost increased by 2.1%. The
share of generic drugs decreased according to DDD/
1000/day, but increased according to financial indicators.
In 2001, the CIHI List of Drugs included either generic
or brand name mood stabilizers (clonazepam, brand
name; carbamazepine and Na-valproate, generics). The
increasing number of generic drugs on the CIHI List
of Drugs was accompanied by the growing number of
brand name drugs. Until 2010, the following new drugs
were introduced: gabapentin (1 brand name and 2 ge-
nerics), oxcarbazepine (1 brand name), pregabalin (1subgroup N03-N06) in the City of Zagreb in 2010
nd name
gs (€)




448.51 359 742.68 57.07 42.93
656.96 11 769.75 0.96 99.04
429.43 1 671 966.84 45.49 54.51
916.08 480 980.28 31.62 68.38
06 451.00 2 524 459.58 44.29 55.71
Table 6 Outpatient utilization of psychopharmaceuticals (ATC subgroup N03-N06) in the City of Zagreb in 2010
according to DDD/1000/day




Total DDD/1000/day Share of generics%
DDD/1000/day
Share of brand name
drugs% DDD/1000/day
N03AE-AX Antiepileptics 3.39 3.21 6.49 51.36 49.46
N04 AA Anticholinergics (biperiden) 0.01 0.9 0.91 1.1 98.9
N05 Psycholeptics 62.54 13.71 76.25 82.02 17.98
N06A Antidepressants 8.17 12.34 20.51 39.83 60.17
Total 74.11 30.16 104.27 71.08 28.92
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addition, new lamotrigine (6 generics) and topiramate (2
generics) drugs were included.
In 2010, there was choice between generic and brand
name lamotrigine and gabapentin. Clonazepam, oxcarba-
zepine, pregabalin and levetiracetam were only available
as brand name drugs, and carbamazepine, Na-valproate
and topiramate as generic drugs [10,19]. The utilization
of generic lamotrigine according to DDD/1000/day was
significantly lower as compared with the brand name
drug (0.27:1.0), whereas the utilization of generic and
brand name gabapentin was quite comparable (0.10:0.13).
Although physicians may want to consider more intensive
monitoring of high-risk patients taking antiepileptic drugs
when any medication change occurs, in the absence of
better data, there is little evidence-based rationale to chal-
lenge the implementation of generic substitution for anti-
epileptic drugs in most cases [27]. Results of some other
studies that compared the use of generic and brand name
lamotrigine in patients with epilepsy and bipolar disorder
also report no statistically significant difference either ac-
cording to plasma drug concentration or exacerbation of
the disease main symptoms [28,29].
During the study period, the highest share of generic
versus brand name drug utilization was recorded for psy-
choleptics (N05) according to both financial indicators
and DDD/1000/day, in spite of the respective decline by
11% and 1.9%. Total cost of hypnotics and sedatives in-
creased by 130%, however, significantly more for brand
name (270%) than for generic agents (124%). In the sub-
group of hypnotics and sedatives, either generic (fluraze-
pam, nitrazepam, zolpidem) or brand name (midazolam)
agents were included in the CIHI List of Drugs in 2001Table 7 Outpatient utilization of psycholeptics (ATC subgroup
indicators
ATC code Therapeutic subgroup Generic drugs (€) Bran
drug
N05A Antipsychotics 292 507.98 728 4
N05B Anxiolytics 367 389.77 155 8
N05C Hypnotics and sedatives 100 639.65 5923
N05 Psycholeptics 760 537.41 911 4[10]. Among generic drugs, nitrazepam showed highest
utilization (6.24 DDD/1000/day), followed by zolpidem
(1.74 DDD/1000/day), and flurazepam (0.46 DDD/1000/
day). The use of midazolam (brand name drug) was only
0.1 DDD/1000/day. In the study period, a new hypnotic
zaleplon (1 generic) and a new zolpidem (1 generic) were
added to the Supplementary list [20].
In 2010, physicians could choose prescribing either
generic or brand name hypnotic and sedative, although a
greater number of generic drugs were available as com-
pared with 2001 [19].
The options included generic flurazepam, nitrazepam
and zolpidem on the main list versus more expensive
zaleplon on the supplementary list [19,20]. Of brand
name agents, only midazolam was available. Among gen-
eric agents, zolpidem was most commonly prescribed
(12.57 DDD/1000/day), so its consumption increased
considerably from 2001; it was followed by nitrazepam
(2.2 DDD/1000/ay), flurazepam (0.4 DDD/1000/day) and
zaleplon (0.05 DDD/1000/day) from the supplementary
list. However, utilization of the brand name drug mid-
azolam increased to 0.33 DDD/1000/day in 2010.
In the therapeutic subgroup of antipsychotics (N05A),
the share of generic drugs decreased significantly from
2001, by 30.9% according to DDD/1000/day, but in-
creased by 8.5% according to financial indicators. Total
cost of antipsychotics also increased by 21.1% (brand
name drugs by 17.4% and generic drugs by 31%). In
2001, either generic or brand name drugs were included
in the CIHI List of Drugs. Of typical antipsychotics, the
brand name agents levopromazine, perazine and thiori-
dazine, or generic agents promazine and fluphenazine
were prescribed. Levopromazine, a typical antipsychoticN05) in the City of Zagreb in 2010 according to financial
d name
s (€)




06.31 1 020 914.29 28.65 71.35
72.08 523 261.85 70.21 29.79
.39 106 563.04 94.44 5.56
29.43 1 671 966.84 46.26 53.74
Table 8 Outpatient utilization of psycholeptics (ATC subgroup N05) in the City of Zagreb in 2010 according to
DDD/1000/day




Total DDD/1000/day Share of generics%,
DDD/1000/day
Share of brand name
drugs% DDD/1000/day
N05A Antipsychotics 3.93 4.49 8.42 46.67 53.33
N05B Anxiolytics 43.43 8.88 52.31 83.02 16.98
N05C Hypnotics and sedatives 15.18 0.34 15.52 97.81 2.19
N05 Psycholeptics 62.54 13.71 76.25 82.02 17.98
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in the interim replaced by a generic drug.
Of atypical antipsychotics, the brand name agents (clo-
zapine, olanzapine and risperidone) or generic agents
(sulpiride) could be prescribed [10]. In 2010, the number
of generic antipsychotics, both typical and atypical, in-
cluded in the CIHI List of Drugs increased since a num-
ber of new atypical antipsychotics were added to the List
in the study period: quetiapine (2 brand name and 3 ge-
nerics), ziprasidone (1 brand name and 1 generic), ser-
tindole (1 brand name), zuclopentixol (2 brand name)
and amisulpride (1 brand name). At the same time, the
number of formulations of the antipsychotics previously
present on the List increased, as follows: promazine (1
generic), clozapine (1 brand name), olanzapine (1 brand
name and 5 generics) and risperidone (5 generics) [19].
Concerning typical antipsychotics, only generic drugs
could be prescribed in 2010. Of atypical antipsychotics,
the following generic drugs could be prescribed: ziprasi-
done, clozapine, olanzapine, quetiapine, sulpiride and
risperidone. The following brand name agents were in-
cluded in the CIHI List of Drugs: sertindole, zuclopen-
tixol and amisulpride. Among atypical antipsychotics,
there was choice between generic and brand name zipra-
sidone, clozapine, olanzapine, quetiapine and risperidone
[19]. According to DDD/1000/day, the utilization of the
generic olanzapine was significantly lower as compared
with the brand name drug (0.58:2.2), while the respect-
ive ratio was lower in case of risperidone (0.32:0.52).
While there was no utilization of the generic ziprasidone,Table 9 Comparison of outpatient utilization of generic drugs
Zagreb in 2001 versus 2010 – generic drug/brand name drug
ATC code Financial indicators
Ratio generics/originators Ratio generics/originat
2001 2010
N03AE-AX 0.84 1.33
N04 AA 0.00 0.01
N05 1.08 0.83
N06A 0.91 0.46
Total 0.98 0.80clozapine and quetiapine, their respective brand name
drugs were used as follows: ziprasidone 0.22, clozapine 0.7
and quetiapine 0.68 DDD/1000/day.
The declining trend recorded in the utilization of gen-
eric antipsychotics could in part be attributed to the de-
creasing use of typical antipsychotics (only generic agents
included in the CIHI List of Drugs in 2010) and the in-
creasing use of atypical antipsychotics, where ever more
generic and brand name drugs were available, and physi-
cians tended to more frequently prescribe the more ex-
pensive brand name ones. Considering quite frequent
therapy noncompliance in schizophrenics (40%-50% ac-
cording to some authors), which can, among others, be
due to therapy related factors, physicians are probably re-
luctant to prescribe generic drugs [30,31]. Depression,
schizophrenia and bipolar disorder are very complex dis-
orders; therefore physicians avoid switching their therapy,
especially if the patient’s state remains stable on particular
medication. Based on the German pharmacoeconomic
models, it is concluded that the effects of the brand name
risperidone substitution with generic drug are not cost ef-
fective if resulting in reduced patient compliance. The lack
of compliance leads to poorer disease control, which in
turn has unfavorable effects on the patient’s quality of life,
increases the rate of hospitalization, and eventually in-
creases the overall cost of treatment [32]. Similar results
have also been reported for generic versus brand name
clozapine [33]. However, this has not been the case with
more recent formulations of generic clozapine, or espe-
cially generic olanzapine. Relapse rates were similar infrom the main ATC group N (N03-N06) in the City of
ratio
DDD/TID
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and no untoward side effects were seen in any patient pre-
scribed generic olanzapine [34].
Trend in the utilization of the anticholinergic biperiden
used in the management of these disorders can be taken
as an indirect indicator of the psychopharmaceutical pre-
scribing quality, i.e. a reduced rate of extrapyramidal side
effects [35]. Although total consumption of biperiden de-
creased during the study period, the share of generic
biperiden in total utilization increased due to the fact that
only the brand name drug was included in the CIHI List
of Drugs in 2001, whereas generic biperiden was added
along with the brand name drug in 2010 [10,19].
In 2010, a decline was recorded in the utilization of gen-
eric anxiolytics relative to total anxiolytic utilization, by
19.4% according to financial indicators and by 2.7% ac-
cording to DDD/1000/day. At the same time, a greater
number of generic anxiolytics were included in the CIHI
List of Drugs. New generic formulations of alprazolam
were introduced, i.e. 1 on the essential list and 2 on sup-
plementary list. Considering all psychopharmaceuticals,
total cost decreased only for anxiolytics (by 6%), although
the cost increased for brand name drugs and decreased
for generic drugs. In 2001, the generic drugs diazepam,
oxazepam, lorazepam and meprobamate were included in
the CIHI List of Drugs, while physicians could choose be-
tween generic and brand name alprazolam. In 2010, they
could choose between generic and brand name diazepam
and alprazolam, and generic oxazepam and lorazepam. Di-
azepam and alprazolam were included in the essential list,
while oxazepam, lorazepam and alprazolam were included
in the supplementary list [19,20].
The utilization of generic diazepam was tenfold the
utilization of brand name diazepam (16.26:1.66 DDD/
1000/day), while the utilization of generic alprazolam
was twofold the utilization of brand name alprazolam
(8.25:6.68 DDD/1000/day).
Many industrialized countries have enacted an array
of concrete measures aimed at rationalization of drug
utilization, such as defining the price of generic prod-
ucts, stimulating pharmacists to issue generic products,
and giving priority to generic products on the lists of in-
surance companies [4,8,9,36,37]. In Austria, the price of
brand name and generic drugs is regulated so that the
price of a third generic must be at least 60% below the
single-sourced prices to be reimbursed, which stimu-
lated the market to lower prices, for successive branded
generics in particular [4]. Lithuania has demonstrated
that even small countries can have low prices of generic
drugs [38].
In Croatia, drug prescribing is characterized by con-
tinuous efforts to use the restrictive financial resources
for drugs in the most rational way. With this in mind,
various administrative measures were launched on severaloccasions, but of limited duration, such as a limited num-
ber of prescriptions per patient per year [39].
During 2009 and 2010, drug pricing and reimburse-
ment were also revised as part of the health reform, in
order to improve the value for money and decision mak-
ing efficacy, while at the same time enabling the practice
of ethical drug promotion [16]. The following measures
were most relevant:
1. The first generic available will have the price set 30%
below the originator and each subsequent generic
will be 10% below the previous generic on the
Croatian positive list [8].
2. If a medicine is considered eligible for
reimbursement, it will be put on one of two positive
lists: List A, essential list providing 100%
reimbursement of the reference price for listed
products, and List B, supplementary list where
patients are charged co-payments [8].
3. A reference price system is a pharmaceutical
reimbursement element in which identical or similar
products are clustered in so-called reference groups.
Reference prices are determined on the basis of the
lowest price of a product which recorded at least
5% of sales within a therapeutic group over a
twelve-month period to avoid the possibility of
market shortages [8].
A key element in the Croatian reimbursement system is
reference price system, while generic substitution is nei-
ther mandatory nor motivated by a financial incentive that
could serve as a positive factor for increasing generic up-
take. In Croatia, incentives for generic promotion are not
considered necessary since the Social Insurance pays the
reference prices, and as a consequence most manufac-
turers lower their prices to avoid co-payments [8].
Although the demand-side measures have been suc-
cessfully implemented in Croatia, having resulted in
improved renin-angiotensin prescribing efficiency [9], it
does not hold for psychopharmaceuticals. The mea-
sures undertaken for rationalization of psychopharma-
ceutical utilization in Zagreb and Croatia during the
study period failed to fulfill the set goal completely.
The main reason for this failure lies in the fact that the
measures undertaken in Croatia generally referred to drug
pricing, including lowering the price of generic drugs,
while numerous other demand-side measures counter-
poising commercial pressures and encouraging prescrib-
ing generic drugs failed to take place. Similar to this, in
Scotland and Belgium, the introduction of generic ris-
peridone as the sole measure did not increase the overall
utilization of risperidone because it was not accompan-
ied by the specific additional measures to stimulate its
utilization [36,40,41].
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the still great impact of pharmaceutical industry market-
ing continue favoring the ever increasing prescribing
brand name drugs, thus making the overall drug cost
ever more expensive. More specific findings include the
fact that both suply and demand-side reforms are essential
to maximize prescribing efficiency [6,42]. Combining the
initiatives to lower the price of generics with demand-side
measures to enhance their prescribing is important to
maximize prescribing efficiency. Just addressing one com-
ponent will limit the potential efficiency gains. Demand-
side measures based on the four “E”s include educational
activities, engineering activities, economic intervention
and enforcement [6].
There is a potential to achieve some savings with generic
atypical anitpsychotic drugs. However, this is limited by the
complexity of the disease area, so multiple measures are
needed to change the physician prescribing habits. Author-
ities cannot rely on any ‘spillover’ effects to affect future
prescribing, even in closely related classes [36,40,41].
One of the limitatations of this study was the limita-
tion of the DDD methodology itself, as the defined daily
dose does not necessarily reflect the recommended or
prescribed daily dose. This methodology provides only a
rough estimate of consumption and not an exact picture
of actual use. Data on the diagnoses for which the drugs
were prescribed would also have been useful in further
study.Conclusions
During the ten-year period of observation, a decrease in
the share of generic psychopharmaceuticals in total drug
utilization was recorded by both DDD/1000/day and by
financial indicators, in spite of the fact that the number
of generic drugs included in the CIHI List of Drugs
increased.
The greatest decline was recorded in the therapeutic
subgroup of antidepressants (46%), followed by mood
stabilizers (32%) and antipsychotics (30.9%), while the
least decrease was found in the subgroup of hypnotics
and sedatives (1%).
Total cost of psychopharmaceuticals increased by
20.1%, 32.7% for brand name and 7.4% for generic agents.
Total cost of antidepressants increased by 32.6%, whereby
the cost of generic drugs decreased by 12.3% and the cost
of brand name drugs increased by 73.6%. Total cost also
increased for the subgroups of hypnotics and sedatives
(130%) and of antipsychotics (21.1%), while a decrease was
only recorded for the subgroup of anxiolytics (6%).
Although mental disorders are very complex dis-
eases and physicians are reluctant to switch therapy,
there is still room for additional savings and more
rational utilization of psychopharmaceuticals throughstimulating the use of generic drugs, along with indi-
vidualized therapy protocols.
To achieve this goal, additional, specific measures are
needed to stimulate prescribing generic antidepressants
and antipsychotics. These measures should include target
education on the quality, safety and efficacy of generic
drugs, national guidelines, transparent method of generic
drug pricing, defining the criteria for adding a generic
product on the CIHI List of Drugs, quality control of gen-
eric products on the market, and ensuring supply with the
generic drugs included in the CIHI List of Drugs. Restrict-
ive prescribing measures can also prove useful.
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